Oxytocin Is a Positive Allosteric Modulator of κ-Opioid Receptors but Not δ-Opioid Receptors in the G Protein Signaling Pathway.
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
/ pharmacology
Allosteric Regulation
/ drug effects
Animals
Binding Sites
CHO Cells
Cricetulus
Cyclic AMP
/ metabolism
Diprenorphine
/ pharmacology
Dynorphins
/ pharmacology
Electric Impedance
Endocytosis
/ drug effects
GTP-Binding Proteins
/ metabolism
HEK293 Cells
Humans
Inhibitory Concentration 50
Oxytocin
/ pharmacology
Receptors, Opioid, delta
/ agonists
Receptors, Opioid, kappa
/ agonists
Signal Transduction
/ drug effects
G-protein signaling pathway
kappa-opioid receptor
opioid receptor
opioids
oxytocin
positive allosteric modulator
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
04 10 2021
04 10 2021
Historique:
received:
15
09
2021
revised:
29
09
2021
accepted:
29
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Oxytocin (OT) influences various physiological functions such as uterine contractions, maternal/social behavior, and analgesia. Opioid signaling pathways are involved in one of the analgesic mechanisms of OT. We previously showed that OT acts as a positive allosteric modulator (PAM) and enhances μ-opioid receptor (MOR) activity. In this study, which focused on other opioid receptor (OR) subtypes, we investigated whether OT influences opioid signaling pathways as a PAM for δ-OR (DOR) or κ-OR (KOR) using human embryonic kidney-293 cells expressing human DOR or KOR, respectively. The CellKey
Identifiants
pubmed: 34685631
pii: cells10102651
doi: 10.3390/cells10102651
pmc: PMC8534029
pii:
doi:
Substances chimiques
Receptors, Opioid, delta
0
Receptors, Opioid, kappa
0
Diprenorphine
1F0L5N25ZZ
Oxytocin
50-56-6
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
67198-13-4
Dynorphins
74913-18-1
Cyclic AMP
E0399OZS9N
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
ID : 18K07404
Organisme : Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
ID : 20K07750
Organisme : Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
ID : 21K06584
Références
J Pharmacol Exp Ther. 2015 Jan;352(1):98-109
pubmed: 25320048
Brain Res. 2003 Sep 5;983(1-2):13-22
pubmed: 12914962
Trends Pharmacol Sci. 2007 Aug;28(8):382-9
pubmed: 17629965
J Biol Chem. 2015 Aug 7;290(32):19478-88
pubmed: 26100627
Recept Channels. 1993;1(3):233-41
pubmed: 7522902
Cell Rep. 2017 Nov 7;21(6):1681-1691
pubmed: 29117570
Peptides. 2011 Jun;32(6):1255-61
pubmed: 21439337
Endocr Rev. 2010 Feb;31(1):98-132
pubmed: 19903933
Eur J Neurosci. 2008 Aug;28(3):546-58
pubmed: 18702726
Sci Signal. 2018 Aug 07;11(542):
pubmed: 30087177
Front Pharmacol. 2020 Sep 16;11:581544
pubmed: 33071793
Methods Mol Biol. 2015;1335:277-94
pubmed: 26260607
Br J Pharmacol. 2012 Mar;165(6):1659-1669
pubmed: 22023017
Sci Rep. 2015 Dec 21;5:18540
pubmed: 26688325
Front Psychol. 2017 Sep 07;8:1520
pubmed: 28936190
Anesthesiology. 2011 Dec;115(6):1363-81
pubmed: 22020140
Endocrinology. 2021 Feb 1;162(2):
pubmed: 33367612
Front Pharmacol. 2019 Apr 17;10:407
pubmed: 31057409
Br J Pharmacol. 2019 Jun;176(11):1649-1663
pubmed: 30710458
Brain Res. 1993 Apr 16;608(2):181-5
pubmed: 7684311
FEBS Lett. 1993 Aug 30;329(3):291-5
pubmed: 8103466
Physiol Rev. 2001 Apr;81(2):629-83
pubmed: 11274341
Neuropharmacology. 2015 Dec;99:600-9
pubmed: 26318102
Curr Top Med Chem. 2020;20(31):2822-2829
pubmed: 33115393
J Pain. 2007 Jan;8(1):85-90
pubmed: 17097925
Peptides. 2007 May;28(5):1113-9
pubmed: 17420069
Br J Pharmacol. 2018 Jul;175(14):2846-2856
pubmed: 28419415
Mol Pharmacol. 2010 Sep;78(3):456-65
pubmed: 20547734
J Neurosci Methods. 2009 Mar 15;177(2):285-8
pubmed: 19007812
J Med Chem. 2015 May 28;58(10):4220-9
pubmed: 25901762
Brain Res. 2006 Apr 7;1081(1):126-37
pubmed: 16497280
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10830-5
pubmed: 23754417
J Neurosci. 2007 Oct 24;27(43):11614-23
pubmed: 17959804
Neuroendocrinology. 2004;79(4):197-203
pubmed: 15153753
Psychother Psychosom. 2020;89(3):185-187
pubmed: 31865357
Annu Rev Med. 2016;67:433-51
pubmed: 26332001
J Chem Inf Model. 2015 Sep 28;55(9):1836-43
pubmed: 26347990
J Neurosci. 2010 Jun 16;30(24):8274-84
pubmed: 20554879
Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13
pubmed: 12479250
Nat Rev Drug Discov. 2009 Jan;8(1):41-54
pubmed: 19116626
ACS Chem Neurosci. 2017 Jun 21;8(6):1147-1158
pubmed: 28368571
J Pharmacol Exp Ther. 2013 Mar;344(3):708-17
pubmed: 23300227
Horm Behav. 2001 Sep;40(2):133-8
pubmed: 11534973
ACS Chem Biol. 2016 May 20;11(5):1220-9
pubmed: 26841170
Molecules. 2020 Sep 16;25(18):
pubmed: 32948048
J Pharmacol Sci. 2019 Jun;140(2):171-177
pubmed: 31320243
Neurosci Lett. 1996 Jul 12;212(2):87-90
pubmed: 8832645
Brain Res. 2002 Feb 15;927(2):204-7
pubmed: 11821014
Sci Signal. 2016 Nov 29;9(456):ra117
pubmed: 27899527
Mol Pharmacol. 2018 Feb;93(2):157-167
pubmed: 29233847
Nature. 2016 Sep 8;537(7619):185-190
pubmed: 27533032
J Neurosci. 2012 Oct 10;32(41):14109-17
pubmed: 23055480
J Chem Inf Model. 2016 Mar 28;56(3):563-70
pubmed: 26863088
J Pharmacol Sci. 2014;126(4):302-9
pubmed: 25421710
Neuropsychopharmacology. 2018 Dec;43(13):2514-2520
pubmed: 30250308
Pharmacol Rep. 2018 Jun;70(3):577-583
pubmed: 29679881
Neurosci Lett. 2010 May 26;476(1):32-5
pubmed: 20371376
Mol Pharmacol. 1993 Jul;44(1):8-12
pubmed: 8393525
Am J Pharmacogenomics. 2003;3(2):117-30
pubmed: 12749729
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12048-52
pubmed: 1334555
Mol Pain. 2008 May 29;4:19
pubmed: 18510735
Psychopharmacology (Berl). 2010 Jun;210(2):137-47
pubmed: 20401607
J Pharmacol Sci. 2018 May;137(1):67-75
pubmed: 29716811